Table 1.
Levels of significance (P) of the differences with respect to SD values and aneuploidy levels.
| TP53 | CEN17 | AML1 | Chromosome 17 | Chromosome 21 | |
|---|---|---|---|---|---|
| CON Vs. ADI |
P < 10-15 | P < 10-14 | P < 10-18 | P < 10-6 | P < 10-13 |
| CON Vs. PRE |
P < 10-9 | P < 10-12 | P < 10-6 | P < 10-7 | P < 10-4 |
| CON Vs. POST |
P > 0.25 | P > 0.25 | P > 0.85 | P < 10-10 | P < 10-5 |
| POST Vs. ADI |
P < 10-7 | P < 10-8 | P < 10-8 | P > 0.55 | P > 0.05 |
| POST Vs. PRE |
P < 10-6 | P < 10-7 | P < 10-6 | P > 0.10 | P > 0.20 |
| ADI Vs. PRE |
P > 0.10 | P > 0.35 | P > 0.5 | P > 0.05 | P < 0.002 |
CON - samples of cancer free subjects (20 cases); ADI - samples of patients with hematological malignancies obtained at diagnosis (20 cases); PRE - samples of patients with hematological malignancies taken prior to alloSCT (14 cases); POST - samples of patients with hematological malignancies taken following alloSCT (10 cases); SD values - columns 1-3; and aneuploidy levels - columns 4 and 5.